Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 19,777 | 447,179 | 424,142 | 33,247 | 5,060 |
| Depreciation Amortization | -2 | -2,328 | -2,316 | -1,896 | -976 |
| Income taxes - deferred | 3,864 | -348,000 | -366,627 | N/A | N/A |
| Accounts receivable | -86,418 | -176,443 | -136,199 | -102,331 | -60,936 |
| Other Working Capital | -69,763 | -194,537 | -149,994 | -85,282 | -48,541 |
| Other Operating Activity | 114,648 | 249,357 | 186,562 | 134,983 | 76,678 |
| Operating Cash Flow | $-17,894 | $-24,772 | $-44,432 | $-21,279 | $-28,715 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -9,813 | 15,263 | 30,834 | 128,500 | -11,659 |
| PPE Investments | -51 | -214 | -147 | -67 | -25 |
| Purchase Of Investment | N/A | -1,250 | -1,250 | -145,359 | -1,250 |
| Investing Cash Flow | $-9,864 | $13,799 | $29,437 | $-16,926 | $-12,934 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -255,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 763 | 1,511 | 453 | 453 | 21 |
| Common Stock Repurchased | -99,992 | -91,240 | -91,240 | -12,998 | -6,123 |
| Other Financing Activity | 745,058 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $390,829 | $-89,729 | $-90,787 | $-12,545 | $-6,102 |
| Beginning Cash Position | 80,490 | 181,192 | 181,192 | 181,192 | 181,192 |
| End Cash Position | 443,561 | 80,490 | 75,410 | 130,442 | 133,441 |
| Net Cash Flow | $363,071 | $-100,702 | $-105,782 | $-50,750 | $-47,751 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,894 | -24,772 | -44,432 | -21,279 | -28,715 |
| Capital Expenditure | -51 | -214 | -147 | -67 | -25 |
| Free Cash Flow | -17,945 | -24,986 | -44,579 | -21,346 | -28,740 |